Argentina trade sanction over intellectual property should be reconsidered, Public Citizen contends.
ARGENTINA TRADE PENALTY RECONSIDERATION URGED BY PUBLIC CITIZEN in a Feb. 4 letter to President Clinton. Public Citizen argues that "the USTR actions against Argentina and the U.S. laws which create barriers to the introduction of generic drugs based upon scientific evidence are backdoor attempts to convey private monopoly power for drugs that do not qualify for patent protection."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth